

Teriflunomide Exposure in Pregnancy Form

Date:							
Patient I.D.:							
Country / Province:	:						
Report Type:							
Initial							
Follow up							
•							
Exposure during p	regnar	ncy:					
☐ Maternal		-					
☐ Paternal							
Paternal Informat	tion:						
Date of Birth (DD		VVVVI	•				
Age:years	-141141141	-1111)	•				
Ethnicity: Asia	n Bla	ck 🗆 (aucasian E	lisnanic	Other specify:		
Weight:					o unon jopeour y .		
Height:c							
Rhesus Factor:							
Medical History							
Risk Factor	Yes	No	Risk Factor		Freque	ency	
				Never	Occasionally	Often	Previously /Quit
Hepatitis			Substance				/ Quit
· · · · · · · · · · · · · · · · · · ·			Abuse				
Hypertension			Alcohol				
Psychiatric			Smoking				
Illness							
Epilepsy							
Diabetes							
HIV							
Other Notable							
Health							
Disorders							
/Conditions:	1						

HIV

Health

Other Notable



Please describe								
Weight: kgs lbs Height: cm in Rhesus Factor: Medical History	MMM-\	aucasi		ther, spec				
Risk Factor	Yes	No	Risk Factor	Frequency				
				Never	Occasionally	Often	Previously /Quit	
Hepatitis			Substance Abuse					
Hypertension			Alcohol					
Psychiatric Illness			Smoking					
Epilepsy								
Diabetes								



Disorders /Conditions									
Immunizations:									
Immunization			Yes, Date (D	D-MMM-Y	YYY):	No			
Rubella									
Toxoplasmosis									
CMV									
Was a contraception If yes, please check	type of on (typ	contr	aception: known) Ora	l contrace;	otion (Pro	gester	one)		
Contraceptive Im				a-uterine o	device				
Oral contraception	•	•		-					
Transdermal con	tracept	tion	L Con	traceptive	injection				
Condom									
History of \square normal History of infertility			mal menstrual	cycles					
First Day of Last Me	nstrua	l Perio	d (LMP) (DD-M	1MM-YYYY):			-	
Estimated Delivery	Date (I	DD-MI	MM-YYYY):						
Specify method of o	alculat	ion: _							
☐ LMP ☐ Ultrasound ☐ Other, please	-		MM-YYYY):						
Did you become pre	gnant	while	on teriflunomi	de? Yes	s No				
If you got pregnant						nation	used?	Yes No	
Teriflunomide Dosa	ge at c	oncept	tion:						
Gestational Age at I	ast Do	se:							
Duration of Treatmo	ent wit	h Proc	luct while Preg	nant:					
Did you become pre					tion? 🔲	Yes 🗆	No		
If yes, was accelerat							_		
If yes, did you becon	ne pres	nant v	within 11 days	of teriflund	omide dis	contin	uation?	」Yes □ No	



If accelerated education			, did you bed	ome pregna	nt within 2 ye	ars of terifl	nomide
PATIENT'S MEI risk factors or other substand during pregna	conditions thate	nt may affe n, hyperte	ct the outconsion, eclam	me of the population	regnancy e.g. es including go	alcohol, sm estational, i	nfections
PREVIOUS OBS		-		-			
Gestation Wee Outcome of th neonatal abno	ne pregnancy i	ncluding ar			-	-	fetal /
Family History Is there any hi abnormalities, No Unknown If yes, please s Blood relation (If yes, specify	story of conge , development own pecify: ship between	al delays o	r hereditary	diseases in	paternal or ma		ly? □Yes
DRUG INFORM supplements t	-			ncluding OT	C medications,	, and dietary	1
			Treatme	ent Dates		Week of p	regnancy
Drug Name	Daily Dose	Route	Start (DD-MMM- YYYY):	Stop (DD-MMM- YYYY):	Indication	Start	Stop
Were administ If yes, which d		continued	due to preg	nancy? 🗌 Y	es No		



PRENATAL TESTING:			
Have any specific tests, e.g. amnio			
sampling, fetal stress test, genetic	screening or other be	en performed during the pregi	nancy so far?
☐Yes ☐ No ☐ Unknown			
If yes, please specify test date and	results:		
Test	Date: (DD-MMM-YYYY)	Results	
PREGNANCY OUTCOME			
Pregnancy Ongoing: Yes No			
If yes, Gestational age: (weeks)			
Number of embryos / foetus(es):			
Last ultrasound scan date (DD-MM			
Normal Abnormal, please spe	ecify:		
Delivery Date: (DD-MMM-YYYY): _		-	
□Vaginal □ Forceps/ventouse	Caesarean section		
Status of amniotic fluid: Clear	☐ Not clear		
Placenta: Normal Abnor	mal		
Medications provided during deliv	ery: 🗌 yes, please sp	ecify	☐ No
Delivery duration:			
Maternal complications or problen	ns related to birth:		
Abortion Date:			
Therapeutic Elective Sp Please, specify reason and any abn		·	





Unspecified:				
At week Complication:				
	(DD-MMM-YYYY): _. d (DD-MMM-YYYY):			
MATERNAL PREGNA If the mother exper collection form and (https://www.canad canada/adverse-rea	ienced an adverse d submit as requeste da.ca/en/health-can	rug reaction during d to the Sponsor ar ada/services/drugs	nd to the Canada	Vigilance Program
Date	Drug	Adverse Event	Outcome	Form Tracking Number
First trimester Follo	w-up (please provid	le details of embryo	o/fetal developme	nt):
Second trimester Fo	ollow-up (please pro	vide details of emb	ryo/fetal develop	ment):
Third trimester Follo	ow-up (please provi	de details of embry	o/fetal developmo	ent):
CHILD INFORMATION Neonate	N:			
Live [Normal]	Live with congenita	al abnormality 🗌 S	Stillbirth at week	
Please specify any a	bnormalities:			
□Full term □ Pren	nature Number of w	reeks Post	-mature Number o	of weeks
Sex: Male	Female			
Height:	cms Weight: _		kgs	
Apgar Scores:			_10 mins	
Head circumference	•	cms		



☐ Breast Fed ☐ Bottle Fed
Neonatal Illness, developmental delay or immaturity? Yes, Please specify No
Corrective treatment Required? Yes, Please specify No
Transfer to ICU or paediatric department? Yes, please provide details of location and contact information No
For additional information, (please provide copies of relevant documentation)
ASSESSMENT OF PREGNANCY OUTCOME
SERIOUSNESS CRITERIA
☐ Non-serious ☐ Congenital anomaly/birth defect ☐ Death of mother or neonate
☐ Involved or prolonged inpatient hospitalization ☐ Life-threatening (immediate risk of death)
Other significant medical events (may jeopardise the patient or require intervention to prevent one of other criteria).
Resulted in persistent or significant disability/incapacity.
REPORTER INFORMATION
Name: Title:
Address:
City:Postal Code:
Country:
Institution: Department:
Phone:Fax:E- mail:
Healthcare professional: Yes No If yes, please specify occupation:
Healthcare professional: Yes No If yes, please specify occupation: Did patient give consent to follow up with their Healthcare Practitioner for pregnancy outcome and at intervals of 1 week, 6, 12 and 24 months post-delivery?



Healthcare	e Practitioner:
Name:	
Address: _	
Phone:	
Email:	